MetLife Investment Management, LLC - Sep 18, 2023 Form 4 Insider Report for Neuberger Berman High Yield Strategies Fund Inc. (NHS)

Role
10%+ Owner
Signature
/s/ Israel Grafstein, Chief Compliance Officer of MetLife Investment Management, LLC
Stock symbol
NHS
Transactions as of
Sep 18, 2023
Transactions value $
$0
Form type
4
Date filed
9/20/2023, 04:18 PM
Previous filing
Sep 19, 2023
Next filing
Oct 31, 2023

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction NHS Floating Rate Senior Note, Series A Note, Due Sep. 18, 2023 Other -5.19M -100% 0 Sep 18, 2023 See Footnotes F1, F3, F4
transaction NHS Floating Rate Senior Note, Series A Note, Due Sep. 18, 2023 Other -5.73M -100% 0 Sep 18, 2023 See Footnotes F1, F3, F4
transaction NHS Floating Rate Senior Note, Series A Note, Due Sep. 18, 2023 Other -8.58M -100% 0 Sep 18, 2023 See Footnotes F1, F3, F4
transaction NHS Floating Rate Senior Note, Series B Note, Due Sep. 18, 2023 Other -26.5M -100% 0 Sep 18, 2023 See Footnotes F1, F3, F4
transaction NHS Series C Mandatory Redeemable Preferred Shares Other -3.97M -100% 0 Sep 18, 2023 See Footnotes F2, F3, F4
transaction NHS Series C Mandatory Redeemable Preferred Shares Other -768K -100% 0 Sep 18, 2023 See Footnotes F2, F3, F4
transaction NHS Series C Mandatory Redeemable Preferred Shares Other -1.34M -100% 0 Sep 18, 2023 See Footnotes F2, F3, F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

MetLife Investment Management, LLC is no longer subject to Section 16 filing requirements. Form 4 or Form 5 obligations may continue.

Explanation of Responses:

Id Content
F1 These Floating Rate Senior Notes matured on September 18, 2023, on which date the Issuer repaid the original principal amount, plus accrued and unpaid interest, which interest is exempt from Section 16 of the Securities Exchange Act of 1934, as amended (the "Exchange Act") pursuant to Rule 16a-9 thereunder.
F2 These Series C Mandatory Redeemable Preferred Shares were redeemed in full by the Issuer at their original purchase price of $12.50 per share, plus accrued and unpaid dividends, which dividends are exempt from Section 16 of the Exchange Act pursuant to Rule 16a-9 thereunder.
F3 These securities are held directly by clients for whom the Reporting Person serves as investment manager.
F4 The Reporting Person disclaims beneficial ownership of the securities reported herein, except to the extent of its pecuniary interest therein, and this report shall not be deemed an admission that the Reporting Person is the beneficial owner of such securities for purposes of Section 16 of the Exchange Act or for any other purpose.